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Abstract
Background: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and frequently
progresses from an actinic keratosis (AK), a sun-induced keratinocyte intraepithelial neoplasia (KIN). Epigenetic
mechanisms involved in the phenomenon of progression from AK to cSCC remain to be elicited.
Methods: Expression of microRNAs in sun-exposed skin, AK and cSCC was analysed by Agilent microarrays. DNA
methylation of miR-204 promoter was determined by bisulphite treatment and pyrosequencing. Identification of
miR-204 targets and pathways was accomplished in HaCat cells. Immunofluorescence and immunohistochemistry
were used to analyze STAT3 activation and PTPN11 expression in human biopsies.
Results: cSCCs display a marked downregulation of miR-204 expression when compared to AK. DNA methylation
of miR-204 promoter was identified as one of the repressive mechanisms that accounts for miR-204 silencing in
cSCC. In HaCaT cells miR-204 inhibits STAT3 and favours the MAPK signaling pathway, likely acting through PTPN11,
a nuclear tyrosine phosphatase that is a direct miR-204 target. In non-peritumoral AK lesions, activated STAT3, as
detected by pY705-STAT3 immunofluorescence, is retained in the membrane and cytoplasm compartments,
whereas AK lesions adjacent to cSCCs display activated STAT3 in the nuclei.
Conclusions: Our data suggest that miR-204 may act as a “rheostat” that controls the signalling towards the MAPK
pathway or the STAT3 pathway in the progression from AK to cSCC.
Keywords: miR-204, Cutaneous squamous cell carcinoma, Actinic keratosis, Sun-induced keratinocyte intraepithelial
neoplasia, DNA methylation, MAPK, STAT3
Background
Cutaneous squamous cell carcinoma (cSCC) is an epi-
dermal keratinocyte derived skin malignant tumor with
an incidence of 16 per 100,000 people in Europe [1].
Chronic solar radiation exposure is the most important
risk factor for cSCC development since cSCC preferen-
tially arises from precancerous lesions such as UV-
induced actinic keratosis (AK) [2]. AK is a keratinocyte
intraepithelial neoplasm (KIN or in situ cSCC) that may
progress to invasive cSCC at a rate estimated between
0.025 and 16 % for an individual lesion per year [3], and
patients with multiple AKs have an annual risk of devel-
oping invasive cSCC ranging from 0.15 to 80 % [4].
While most cSCCs are cured by surgery and/or radio-
therapy, a subset of tumors may show an aggressive clin-
ical behaviour, with increased local recurrences and
metastases [5]. Patients with metastatic cSCC have a
disease-specific survival at 1 year of 44–56 % [6].
The genetic basis for the progression from actinic
keratosis to cSCC is not completely understood [4, 7–10].
TP53 mutations are an early phenomenon already seen in
40 % of in situ cSCC [11]. NOTCH inactivating mutations
have recently been found in ~75 % of cSCC [12] but infor-
mation about their presence in AK is lacking. Although
increased genomic instability is found in cSCC, AKs
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already harbour cytogenetic alterations at several loci [13].
We previously demonstrated that EGFR and MYC gains
are already frequent in AKs and not significantly increased
in invasive cSCC [14, 15]. Thus, further genomic and epi-
genetic studies are needed to better understand the pro-
gression from AK to cSCC.
MicroRNAs (miRNAs) are a class of small non-coding
RNAs that can regulate gene expression of a very broad
set of targets including loci in the protein-coding region
of mRNAs, 5′ UTRs, intronic and intergenic transcripts
and other non–protein-coding RNAs [16]. MiRNAs are
proposed to regulate 60 % of all protein-coding genes in
humans [17]. Every miRNA can have multifunctional
roles as either repressors or enhancers of their targets
expression by diverse pathways [18].
Aberrant miRNA expression is linked to cancer devel-
opment and progression and affects several processes
including proliferation, apoptosis, differentiation and
invasiveness. In cSCC most of the altered miRNAs are
downregulated (miR-125b, miR-34a, miR-214, miR-124,
miR-361, miR-193b, miR-365a, miR-20a, miR-199a)
[19–25] whereas only a small number of miRNAs have
been found to be upregulated and act as onco-miRNAs,
being involved in angiogenesis, colony formation, mi-
gration and invasion, and metastatic spread (miR-365,
miR-9, miR-184, miR-21, miR-31, miR-135b, miR-205,
let-7a) [25–34]. However, most of these miRNAs have
been identified by comparing miRNA expression in
cSCC versus healthy skin, and only few studies were
aimed to compare miRNA expression in AKs and cSCC
[19, 23, 31]. Here we explore the miRNA expression sig-
nature of cSCC and AK to identify miRNAs implicated
in the development and evolution from AK to cSCC.
Methods
Clinical samples
All samples were obtained at the Department of Derma-
tology of Hospital del Mar (Barcelona, Spain) and imme-
diately embedded in OCT and frozen in liquid nitrogen.
Microarray analysis
Four millimeter punch biopsies were taken from moder-
ately differentiated cSCCs (20 lesions in sun-exposed
areas from 20 patients). Five KIN3 actinic keratoses and
5 control chronically sun-exposed (CSE) skin samples
were obtained by shave biopsy from 10 different pa-
tients. Clinicopathological data of the patients can be
found in Additional file 1: Figure S1. Samples were
macrodissected from frozen blocks after examination of
hematoxylin-eosin stained sections such that all samples
displayed a minimum 70 % enrichment for tumor or
dysplastic cells. RNA quality and concentration was
measured using the Agilent Bioanalyser. Only samples
with RIN ≥6 (Bioanalyzer 2100, Agilent Technologies)
were included in the study. RNA (10 ng) was used as tem-
plate for whole transcriptome amplification and cDNA
synthesis. The microarray technology used was Agilent
Human miRNA microarrays (V2, G4470B, Agilent
Technologies, Sanger Database version 10.1). Data
normalization was performed with Feature Extraction
Software (Agilent Technologies). Extracted intensities
were background corrected using the normexp method
with an offset of 50 [35]. Background corrected log2-
transformed intensities were normalized using invariants
normalization to make data from all arrays comparable
[36]. Microarray probes were collapsed to miRNAs by tak-
ing the median intensity of the respective probes per
miRNA. For determining differentially regulated miRNAs
moderated t-tests were applied using Limma (Linear
Models for Microarray Data) [37]. MiRNAs with FDR
adjusted p-value <0.05 and additionally a fold change ex-
ceeding 1.2 in absolute value were selected as the relevant
ones. All statistical analyses were performed with the
Bioconductor project in the R statistical environment [38].
DNA methylation analysis by pyrosequencing
Bisulphite conversion of 500 ng of each DNA sample
was performed with EZ DNA Methylation-Gold Kit
(Zymo Research, Milan Italy) according to the manufac-
turer’s recommendations. PCR for miR-204 promoters
was performed with 1 μl of bisulphite converted DNA
under standard conditions with biotinylated primers
using an annealing temperature of 60 °C. Primer sequences
are: miR-204 Forward (5′-[Btn]TGGTTTTTTTTTAAAT
TAAGTTAGTAAAGT-3′); miR-204 Reverse (5′- ACAAC
CTACACAAAACAACCTATAATC-3′); miR-204 Sequen-
cing (5′-ACAACCTACTCCAAAAT-3′) and were designed
with PyroMark Assay Design 2.0. PCR products were ob-
served on 2 % agarose gels before pyrosequencing analysis.
Reactions were performed in a PyroMark Q96 System
version 2.0.6 (Qiagen, Milan, Italy) and the methylation
values of the CpG dinucleotides were obtained using Pyro
Q-CpG 1.0.9 (Qiagen, Milan, Italy).
Cell culture and expression arrays
HaCaT cells were cultured in DMEM medium (Sigma)
supplemented with 10 % fetal bovine serum in standard
conditions. SCC13 and SCC12 cells were cultured in
DMEM:F12 medium (Sigma) supplemented with 10 %
fetal bovine serum, penicillin–streptomycin (100 mg/ml,
Invitrogen), adenine (180 mM, Sigma), human recom-
binant EGF (10 ng/ml Peprotech), insulin (5 mg/ml,
Sigma), cholera toxin (0.1 nM, Gentaur) and hydrocorti-
sone (0.5 mg/ml, Sigma). Human epidermal keratino-
cytes (HEK, Life Technologies) were cultured in KSFM
medium (Thermo Fisher). To restore the expression of
DNA-methylated miR-204, HaCaT cells were treated
with the DNA demethylating agent 5-aza-2′-
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deoxycytidine (Sigma) at 10 μM for 120 h. To generate
retroviral stocks for stable expression of miR-204 antag-
omir, 293T cells were transfected with Fugene (Roche)
with miRZIP-204 anti-miR-204 construct (shRNA target-
ing miR-204 microRNA, cloned in pGreenPuro HIV
based lentivector, BioCat), or with the corresponding
pGreenPuro scrambled hairpin negative control (BioCat).
HaCaT cells were transduced with lentiviral supernatants
in the presence of Polybrene (4 μg/ml; Sigma). Two days
after the infection, control and miR-204 antagomir ex-
pressing HaCaT cells were FACS-sorted. Total RNA ex-
traction from GFP-positive cells was performed with
Genelute mammalian total RNA kit (Sigma). Samples
were then processed following the protocols provided by
Ambion (Ambion WT Expression, Protocol Number
4425209; Revised B 05/2009) and Affymetrix (Affymetrix
WT Terminal Labeling and Hybridization User Manual,
Protocol Number 702808 and Expression, Wash, Stain
and Scan User Manual Protocol Number 702731). The
expression platform used was Human Gene 2.0 ST
(Affymetrix®).
Transient expression of miRIDIAN microRNA human
hsa-miR-204-5p-hairpin inhibitor (Dharmacon), pre-miR™
miRNA-204-5p precursor (Life Technologies) or the cor-
responding controls (miRIDIAN microRNA hairpin in-
hibitor negative control #1, Dharmacon, and pre-miR™
miRNA precursor negative control #1, Life Technologies,
respectively) at 50 nM was performed with DHARMA-
FECT 4 as described earlier [39]. Twenty four hours
later, cells were treated with 10 ng/ml EGF, IL6 or FGF9
(Peprotech) for the times indicated, in the absence or
the presence of 50 μM NSC87877 (Sigma).
RNA extraction and quantitative reverse transcription PCR
(qRT-PCR)
RNA was extracted from frozen biopsies with the mirVana™
miRNA Isolation Kit (Applied Biosystems). qRT-PCR for
miR-204 transcripts was performed with TaqMan® micro-
RNA assays (Applied Biosystems), using RNU48 levels to
normalize the data. Real-time PCR reactions were per-
formed in triplicate in 384-well plates and were run in a
QuantStudio™ 12K Flex Real-Time PCR System. The 2-
(ΔΔCt) method [40] was used to determine relative quan-
titative levels of miR-204. qRT-PCR to analyze gene ex-
pression was performed using SYBR Green PCR master
mix (Applied Biosystems, Life Technologies) and GAPDH
expression was used as endogenous control for
normalization purposes. Primers used for qRT-PCR
were: PTPN11 (5′- AAAGGGGAGAGCAATGACGG-3′;




2 (5′- CCCCAGAAAACCCGAGCGA-3′; 5′- CGTCCGC
TAATCTGGCACC-3′); CBL (5′- ATTCTCCATGGCC
CCACAAG-3′; 5′- GAATATGGCCGGTCTGGAGG-3′);
MAP3K2 (5′- GACCAACTGGAGATTGGGCA-3′; 5′- G
GTCTCAGGACTATCGGGGT-3′); C1QBP (5′- TTTG
CATCTGCACGTGTTCG-3′; 5′- CAGGAGCTGCCGG
AAAGG-3′); PDP2 (5′- CTTGCAAACACGCCTACT





Protein extraction and Western blot
These protocols were performed following standard
techniques. STAT3 (C-20), ERK2 (C-14) and PTPN11
(SH-PTP2 B1) antibodies were purchased from Santa
Cruz Biotech. Activated MAP kinase (diphosphorylated
ERK1/2) antibody was from Sigma. Lamin B1, Actin,
phospho-Y705-STAT3 and phospho-S727-STAT3 anti-
bodies were from Abcam. HRP-conjugated secondary
antibodies were purchased from Dako. Western blot
quantification was performed using Image J densitom-
etry software. Intensity of individual bands was normal-
ized to Actin signal and referred to control conditions.
Transfection and luciferase assay for PTPN11 3′ UTR
construct
Oligonucleotides corresponding to the PTPN11 3′UTR





ACTTGACAATTGCAAC-3′) were annealed and
inserted in the psiCHECK2 plasmid (Promega), immedi-
ately downstream from the stop codon of Renilla lucifer-
ase, and the sequence was confirmed by sequencing. For
the luciferase assay, the transfection was performed using
Fugene HD (Roche). Once ready, HaCaT cells were trans-
fected with the reporter plasmid along with miR-204
antagomir, miR-204 mimic or with their corresponding
hairpin inhibitor or precursor negative controls at 50 nM.
Renilla and Firefly luciferase activities were measured con-
secutively using a dual-luciferase assay (Promega) 24 h
after transfection. Renilla luciferase activity was normal-
ized to Firefly luciferase activity expressed from the psi-
CHECK2 plasmid.
Immunofluorescence and immunohistochemistry
Immunofluorescence was performed on 4 μm-thick tis-
sue sections of 14 non-peritumoral AKs, 11 cSCC and
their corresponding adjacent AK samples. Heat-induced
antigen retrieval was performed in 10 mM citrate (pH 6)
for 15 min in a pressure cooker. The slides were then
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incubated with STAT3 (phospho-Y705) antibody
(Abcam) for 12 h. After washing, the Envision + antibody
reagent was applied (Dako). Reactions were developed
with the TSA™ Plus Cyanine3/Fluorescein System (Perki-
nElmer). Nuclei were counterstained with Hoesch and
examined with a fluorescence microscope (Olympus
BX61). Cases where pY705-STAT3 signal was detected
in more than 20 % of cells were considered as positive.
PTPN11 immunohistochemistry was performed by anti-
genic retrieval in 10 mM citrate (pH 6) for 15 min in a
pressure cooker. After primary antibody incubation, the
Envision + System-HRP antibody reagent was applied
(Dako) and reactions were developed using diaminobenzi-
dine (DAB, Dako).
Results
Identification of miRNAs differentially expressed in actinic
keratosis (AK) and cutaneous squamous cell carcinoma
(cSCC)
To determine whether any miRNAs was aberrantly
expressed in cSCC and in AK, 20 cSCC, 5 AK and 5
chronically sun-exposed (CSE) skin biopsy specimens
were studied for miRNAs expression with a gene expres-
sion microarray (clinicopathological data, Additional file 1:
Figure S1). Supervised clustering of cSCC vs. CSE skin
expression arrays identified 35 miRNAs differentially
expressed (Fig. 1a). In contrast, supervised clustering of
AK vs. CSE skin identified only two downregulated miR-
NAs, miR-30* and miR-144, whereas no miRNA was found
to be upregulated in AK. Supervised clustering of cSCC vs.
AK identified a unique downregulated miRNA, miR-204
(Logarithmic fold change = −1.2; p = 0.0097) in cSCC,
whereas no miRNA was found to be upregulated. Analysis
of miR-204 expression by qRT-PCR in the 20 cSCC and 5
AK biopsies used for the array confirmed low to undetect-
able levels of this miRNA in cSCC, whereas AK displayed
statistically significant higher levels of miR-204 (Fig. 1b, c).
Independent validation in a different cohort consisting of
45 biopsy samples (15 CSE skins, 15 cSCCs and 15 cSCC-
distant AKs from 15 patients; all lesions were located on
the head and were at least 1 cm and maximum 5 cm apart
from each other) confirmed miR-204 downregulation in
cSCC when compared to intraindividual AKs (Fig. 1d).
MiR-204 expression is frequently silenced by DNA
methylation in cSCC
MiR-204 is an intronic miRNA located at the TRPM3
gene that shares the same promoter and regulatory motif
for transcription than TRPM3 [41, 42]. Pyrosequencing
analysis of three consecutive CpGs (CpG -26, CpG -28,
CpG -40) located at the miR-204 promoter region re-
vealed that this promoter was heavily methylated in the
two cSCC cell lines tested (SCC12 and SCC13) as well
as in the epidermal carcinoma cell line A431, whereas
the immortal keratinocyte cell line HaCaT displayed a
partially methylated miR-204 promoter (Fig. 2a). Next
we determined miR-204 promoter methylation in 5 CSE
skin, 4 AK and 11 cSCC samples. Interestingly, an in-
crease in miR-204 methylation levels was found from
CSE skins to AKs, whereas DNA methylation only ac-
counts for miR-204 silencing in seven of the cSCC sam-
ples (64 %) (cut off >24 %; the highest methylation value
found in CSE skin biopsies) (Fig. 2a, b). Importantly,
treatment of HaCaT cells, which express low but detect-
able miR-204 levels, with the demethylating agent 5-aza-
2′-deoxycytidine partially restored miR-204 expression
(Fig. 2c) suggesting that DNA methylation of the miR-
204 promoter directly impinges on miR-204 expression.
Altogether, these results indicated that different mecha-
nisms account for miR-204 silencing, among them DNA
methylation.
Identification of miR-204 targets in non-transformed
keratinocytes
Overall function of individual miRNAs in oncogenesis
may be context dependent [43]. To determine gene ex-
pression changes induced by miR-204 downregulation in
non-tumoral keratinocytes we infected HaCaT cells with
lentiviral supernatants carrying short hairpin RNA
(shRNA) targeting miR-204 or the corresponding scram-
bled hairpin negative control along with the GFP gene.
Green-positive HaCaT cells were flow cytometry-sorted
and their total RNAs were purified. Differences in gene
expression between both conditions were analyzed by
the Human Gene ST Arrays platform (Affymetrix) (GEO
accession number: GSE71953 and Additional file 1:
Figure S2). To identify molecular and cellular functions
modulated by miR-204 in our cellular context we used
Ingenuity Pathway Analysis (IPA) software. This analysis
revealed that the expression array was significantly over-
represented by proteins that control cell cycle, cellular
movement, cellular development, cellular growth, prolif-
eration and cell signaling. Among the canonical path-
ways and upstream regulators, the FGF-STAT3 signaling
pathway was identified to be deregulated in miR-204-
depleted HaCaT cells (Fig. 3a). IPA software (which
integrates experimentally demonstrated and predicted
microRNA-mRNA interactions) identified a number of
putative direct miR-204 targets (Fig. 3b). Among them,
PTPN11 and FAM117B were also predicted to be miR-
204 targets by the TargetScan 6.2 software [44].
PTPN11 (also called SHP2) is a member of the protein
tyrosine phosphatase (PTP) family that directly affects
STAT activity in A431 cell nuclei [45], while FAM117B
is a protein-coding gene of unknown function expressed
in the nucleus of basal keratinocytes [46]. Because the
FGF-STAT3 pathway was identified to be deregulated in
miR-204-depleted HaCaT we hypothesized that the
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PTPN11 phosphatase could be directly targeted by miR-
204 to modulate STAT3 signaling. To investigate this
possibility, HaCaT cells were transiently transfected with
miR-204 antagomir (hairpin inhibitor), miR-204 mimic
(pre-miRNA-204 precursor) or with the corresponding
antagomir or precursor negative controls (Fig. 3c). Ac-
cording to the gene expression data, miR-204 antagomir
transfected cells displayed lower PTPN11 mRNA levels
than their control antagomir counterparts, whereas the
expression of the miR-204 mimic enhanced PTPN11
levels (Additional file 1: Figure S3A). MiRNAs can si-
lence cytoplasmic mRNA translation either by triggering
an endonuclease cleavage, by promoting translation re-
pression or by accelerating mRNA decapping [47]. Since
miRNAs can interfere with mRNA translation in a man-
ner independent of changes at the mRNA level [47] we
tested miR-204 impact on PTPN11 protein expression.
Contrary to the effect observed on PTPN11 mRNA
levels, transfection of miR-204 antagomir in HaCaT cells
up-regulated PTPN11 protein levels, whereas miR-204
mimic resulted in downregulation of PTPN11 expression
(Fig. 3d). Next, we performed a reporter assay in which
the Renilla luciferase reporter gene was under control of
the PTPN11 3′ UTR. We observed that sequestration of
endogenous miR-204 with the specific antagomir in-
creased the expression of the Renilla reporter, while the
expression of the miR-204 mimic reduced the expression
of the reporter, confirming that PTPN11 may be a pri-
mary target of miR-204 through its 3′ UTR (Fig. 3e).
Finally we validated the microarray data by qRT-PCR
analysis of some differentially expressed genes in HaCaT
cells transfected with miR-204 antagomir or miR-204
mimic (Fig. 3f ). The fact that miR-204 inhibition re-
presses while miR-204 induces the expression of the val-
idated genes suggests that miR-204 might indirectly
regulate their expression. We also tested some cellular
functions identified by IPA as modulated by miR-204 ex-
pression. Cell cycle status assessed by BrdU staining to
detect DNA synthesis revealed that miR-204 depletion
in HaCaT cells impairs BrdU incorporation while cells
transfected with miR-204 mimic displayed an enhance-
ment in BrdU staining (Additional file 1: Figure S3B). In
contrast, cell migration enhancement was observed in
HaCaT cells transfected with miR-204 mimic, whereas
no effect was observed in those transfected with the
antagomir (Additional file 1: Figure S3C). Therefore
gene expression and migration modulation by miR-204
were more effectively observed when this miRNA was
overexpressed, whereas miR-204 depletion mostly re-
sulted in mild gene expression changes and unaffected
cell motility. This could be explained by the relatively
low endogenous miR-204 levels due to partial DNA
methylation of the miR-204 locus in HaCaT cells (see
above), despite being a non-tumorigenic cell line. Since
interfering endogenous miR-204 levels in HaCaT cells
would likely result in subtle gene expression changes,
from then on the analysis of miR-204-mediated changes
was carried out by miR-204 overexpression.
MiR-204 affects the expression of EGF-modulated genes
and regulates STAT3 signaling
The FGF-STAT3 signaling pathway was identified by the
IPA software to be modulated by miR-204 expression in
HaCaT cells. Therefore we checked whether EGF, IL6
and FGFs, all of them capable of activating MAPK and
STAT3 pathways to different extents, modulate the ex-
pression of some of the genes differentially expressed in
our array. HaCaT treatment with EGF for 24 h resulted
in enhanced expression of all the genes tested, but not
IL6 gene, that was used as a negative control. In con-
trast, neither FGF9 nor IL6 were able to modulate the
expression of any of the tested genes, exception made
for FGF9, which seemed to autoregulate its own expres-
sion (Fig. 4a).
Next we tested whether miR-204 overexpression im-
pinged on EGF-induced gene expression. To this end,
HaCaT cells transfected with control or miR-204 mimics
were stimulated with EGF for 30 min or 24 h. MiR-204
mimic-transfected cells displayed higher basal and in-
duced mRNA levels of the tested genes at short time
points. However, mRNA levels of these genes were fur-
ther increased in control cells at 24 h, whereas the levels
of these mRNAs dropped in miR-204 mimic cells
(Fig. 4b). These results indicated that miR-204 expres-
sion modulates EGF signaling intensity and timing, with
an initial activation followed by a downregulation at lon-
ger time periods.
It has been described that EGF stimulation of HaCaT
cells induces MAPK activation but fails to phosphorylate
STAT3 [48, 49], which is only activated in malignant
progression of the keratinocyte towards SCC [50–52].
Therefore, we explored the impact of miR-204 on EGF-
(See figure on previous page.)
Fig. 1 MiR-204 is differentially expressed in AK versus cSCC. a Supervised clustering of cSCC, AK and chronically sun exposed skin (CSES)
expression arrays (left) and identification of differentially expressed miRNAs (right). b MiR-204 expression in cSCC and AK, analyzed by qRT-PCR
and expressed as relative quantitative levels (2-(ΔΔCt) method). c Box plot representation of relative miR-204 levels in AK and cSCC. U-Mann
Whitney test was applied to determine statistical significance. d Validation of miR-204 differential expression in an independent cohort. Dot plot
representation of relative miR-204 levels in CSE skin, AK and cSCC from the same donor (n = 15), and referred to their corresponding miR-204
levels in CSE skin. Wilcoxon test was applied to determine statistical significance
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mediated regulation of MAPK and STAT3 pathways.
HaCaT cells transfected with miR-204 or control mimics
were stimulated with EGF for different time periods up
to 6 h. ERK2 total levels and ERK1/2 phosphorylation
kinetics were similar upon EGF stimulation in both
conditions. Of note, pERK1/2 basal levels were higher in
miR-204 mimic cells (Fig. 5a). In addition, EGF en-
hanced STAT3 total levels during the first hours, drop-
ping to basal levels after 6 h of the treatment, being this
effect stronger in those cells transfected with miR-204
Fig. 2 DNA methylation-associated silencing of miR-204 in cSCC cell lines and human samples. a Up, schematic representation of TRPM3/miR-204
gemomic locus. Down, DNA methylation levels of the miR-204 promoter region in cell lines and human biopsies. Methylation levels represent the
mean of three consecutive CpGs (-26, -28, -40) located at the promoter region of miR-204. Error bars indicate standard deviation. b DNA methylation
and expression levels of miR-204 in human biopsies detected by qRT-PCR. c Relative miR-204 levels in human epithelial keratinocytes and HaCaT cells,
and restored expression of DNA methylated miR-204 in HaCaT cells after treatment with the DNA demethylating agent 5-aza-2′-deoxycytidine (Aza).
Values were determined in triplicates by quantitative RT–PCR and are expressed as mean ± SD (n = 3)
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Fig. 3 Identification of gene expression changes upon miR-204 downregulation in the non-tumorigenic HaCaT cell line. HaCaT cells infected with
anti-miR-204 lentivirus (shRNA targeting miR-204) or with the corresponding pGreenPuro scrambled hairpin negative control lentiviral supernatant
were flow cytometry-sorted and their total RNAs were purified. Differences in gene expression between both conditions were analyzed by the
Human Gene ST Arrays platform (Affymetrix). a Ingenuity Pathway Analysis (IPA) identification of the molecular and cellular functions, top canonical
pathways and upstream regulators. b In silico identification by IPA of putative direct miR-204 targets differentially regulated in HaCaT cells. c MiR-204
expression relative to RNU48 measured by qRT-PCR in HaCaT cells transfected with miR-204 antagomir or miR-204 mimic along with their appropriate
controls. d PTPN11 expression is up-regulated by miR-204 in HaCaT cells, monitored by Western blot. e Relative Renilla luciferase activity derived from
the PTPN11 3′ UTR reporter construct monitored after transfection of HaCaT cells with miR-204 antagomir or miR-204 mimic, along with their controls.
f Independent validation of miR-204 regulation of some of the genes identified by the expression array, by HaCaT transient transfection of miR-204
antagomir or mimic along with their controls. Mean ± SD of three replicate samples from one representative experiment
Fig. 4 EGF induction of miR-204 modulated genes in HaCaT cells. a HaCaT cells were treated with EGF, FGF9 or IL6 (10 ng/ml). Twenty four hours
later, total RNA was extracted and mRNA levels of the different transcripts were determined by qRT-PCR. Mean ± SD of three replicate samples
from one representative experiment out of two. b HaCaT cells were transiently transfected for 24 h with miR-204 mimic or control mimic
molecules and treated with EGF (10 ng/ml) for the indicated time points. Mean ± SD of three replicate samples from one representative
experiment out of two
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mimic. Basal pY705-STAT3 levels were undetectable
both in control as well as in miR-204-overexpressing
cells. EGF treatment induced a biphasic STAT3 phos-
phorylation at Y705 in miR-204 overexpressing cells in
the first hours, whereas pY705-STAT3 was barely detect-
able in control cells (Fig. 5a).
The miR-204 target PTPN11 can modulate STAT3
[53–55]. Accordingly, the kinetic of PTPN11 expression
after the stimulation with the cytokine closely resembled
that of total STAT3 and, as observed for STAT3, enhanced
PTPN11 expression was stronger in miR-204 mimic cells
than control cells at these time points (Fig. 5a).
Fig. 5 Effects of miR-204 overexpression on MAPK and STAT3 signaling pathways. a HaCaT cells were transiently transfected for 24 h with miR-204 or
control mimics, and treated with EGF (10 ng/ml) for the indicated time points. Total extracts from these cells were subjected to western blot analysis
(left). Intensity of individual bands was normalized to Actin signal, as a measure of protein relative abundance in the different samples and referred to
control conditions, using Image J densitometry software (right panels). b Control or miR-204 mimic transfected HaCaT cells were treated with EGF,
FGF9 or IL6 (10 ng/ml) for 24 h. Total extracts from these cells were subjected to western blot analysis (left). Intensity of individual bands was
normalized to Actin signal, as a measure of protein relative abundance in the different samples and referred to control conditions, using Image J
densitometry software (right panels). c HaCaT cells were treated with EGF, FGF9 or IL6 (10 ng/ml) for 24 h, in the absence or in the presence of 50 μM
NSC87877, and processed as in b
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STAT3 can be activated in a biphasic pattern, with a
first wave of activation within 1 h of cytokine treatment
and a sustained wave in which STAT3 remains active for
many hours [56]. One of the cytokines able to induce
sustained STAT3 activation is IL6 [56]. We analysed
MAPK and STAT3 pathways after 24 h of treatment
with EGF, FGF9 and IL6. At this time point pERK1/2
levels were higher in miR-204 mimic cells stimulated
with EGF, FGF9 and IL6 (Fig. 5b). In contrast, control
cells displayed enhanced STAT3 expression by FGF9 and
IL6 and sustained Y705-STAT3 phosphorylation by IL6
that were not observed in miR-204 overexpressing cells.
It has been reported that Y705-STAT3 phosphorylation
can be negatively modulated by ERK induced phosphor-
ylation of S727-STAT3 [57]. However, similar levels of
S727 phosphorylation could be observed regardless miR-
204 expression. PTPN11 levels were higher in untreated
cells as well as upon FGF9 and IL6 treatments in control
cells when compared to similar conditions in miR-204
overexpressing cells at this time point. All these data in-
dicated that miR-204 induced STAT3-mediated signaling
at short time points but resulted in impairment in
STAT3 expression and activation triggered by different
cytokines signaling through this pathway at longer time
points.
PTPN11 has been previously reported to regulate
the STAT3 signaling pathway in different cellular con-
texts. To directly address its role in our experimental
conditions, HaCaT cells were stimulated for 24 h with
EGF, FGF9 and IL6 in the presence of NSC87877, that
specifically inhibits PTPN11 [58], and activated and
total STAT3 levels were analysed by western blot.
Control cells displayed sustained Y705-STAT3 phosphor-
ylation and enhanced STAT3 expression by IL6 that were
not observed in NSC87877 treated cells (Fig. 5c). This re-
sult parallels that of the effect of IL6 in miR-204 overex-
pressing HaCaT cells, supporting the notion that PTPN11
mediates, at least in part, some of the miR-204 regulatory
effects on STAT3 signaling pathway.
Differential subcellular localization of pY705-STAT3 in
non-peritumoral and cSCC-adjacent AKs
It has been reported that about 80 % of cSCCs display
STAT3 activation, localized mainly in the nuclei. Inter-
estingly, AKs also displayed STAT3 activation if the adja-
cent SCC was positive for STAT3 phosphorylation signal
[59, 60]. Since our in vitro data suggested that miR-204
expression in AK would impair long term activation
of STAT3 signaling, we investigated pY705-STAT3
localization in 14 non-peritumoral AKs, 11 cSCCs and
in their adjacent corresponding AKs. Four of non-
peritumoral AKs displayed poor pY705-STAT3 signal
and 10 AKs (71 %) displayed pY705-STAT3 signal in
the cell membrane and/or cytoplasm, whereas CSE
skin was negative (Fig. 6a). In contrast, 9 out of 11
cSCC biopsies and their adjacent AKs (82 %) displayed
nuclear pY705-STAT3 signal (Fig. 6a, b), suggesting that
STAT3 activation and nuclear localization in AK and
cSCC inversely correlate with miR-204 expression. Im-
portantly, nuclear pY705-STAT3 signal in cSCC samples
was consistently found in regions closer to the epidermis,
whereas deeper and more invasive regions of the tumors
were negative for STAT3 activation (Fig. 6b), pointing to
an essential role in early stages of the tumorigenesis but
not in cSCC progression. PTPN11 was not detected in
CSE skins or in distant AKs, whereas cSCC-adjacent AKs
displayed nuclear expression (Fig. 6c), suggesting that
PTPN11 regulation of STAT3 transcriptional activity takes
place in the nucleus.
Discussion
MiRNAs alterations are involved in the development of
several skin cancers [61]. We have identified miR-204,
previously found to be down-regulated in head and neck
squamous cell carcinoma (HNSCC) [62, 63] and cSCC
[25], as the only miRNA to be significantly down-
regulated in cSCC when compared to AK. MiR-204 is
located at 9q21.1-q22-3, a cancer-associated genomic re-
gion exhibiting a high frequency of loss of heterozigosity
(LOH) in HNSCC, but rarely lost in cSCC. DNA methy-
lation represents the most studied epigenetic regulatory
mechanism of modifying gene expression in both coding
and non-coding genes such as microRNAs [64–67]. We
here report hypermethylation of the miR-204 promoter
in AKs and in a high proportion of cSCCs. Since this
genomic region also displays STAT3-binding sites, and
phosphorylated STAT3 suppresses miR-204 expression
in pulmonary arterial hypertension [68], STAT3 activa-
tion by alterations in proteins modulating this pathway
could account as an alternative mechanism for miR-204
dowregulation in cSCC [69]. Therefore, different DNA-
methylation dependent and independent mechanisms
could mediate miR-204 repression in cSCC.
Several studies in epithelial cell lines have shown
that members of the miR-200 family are repressed
during epithelial-to-mesenchymal transition (EMT)
[70]. Some in vitro studies with hepatic, renal, ovarian
and breast cancer cell lines have shown that loss of
miR-204 results in activation of an EMT, leading to
cancer cell migration and invasion [71, 72]. We have
previously described that EMT is common in meta-
static cSCC [73]. Although we have not detected a
relationship between miR-204 and EMT, the demon-
stration of miR-204 silencing in cSCC samples regard-
less of their biological behaviour makes unlikely the
possibility that miR-204 plays a relevant role in this
process.
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All miRNAs have complex multifunctional and cell
context-dependent roles as either repressors or en-
hancers [18]. Accordingly, we observed a positive
short-term induction of the STAT3 pathway by miR-
204, whereas in the long-term miR-204 downregulates
STAT3 pathway, while favouring MAPK pathway acti-
vation. Conversely, low levels of miR-204 in cSCC
would favour STAT3 pathway activation, which is also
mediated by IL6 [56]. In pulmonary hypertension an
auto-regulatory positive feedback has been reported, in
which STAT3 activation might perpetuate miR-204
downregulation [74].
The MAPK/ERK pathway is the most important cell
survival pathway in non-tumorigenic keratinocytes, and
is triggered by EGF. Forced expression of EGFR in immor-
talized keratinocytes (HaCaT cells) has been associated
with enhanced EGFR activation but not with Y705-STAT3
phosphorylation [51]. In contrast, malignant progression
of the keratinocyte towards SCC is associated with
negative MAPK regulation and EGFR-induced STAT3
activation [50–52], which drives expression of multiple
antiapoptotic molecules [50, 52, 75–78]. Accordingly,
STAT3 expression was found to be consistently increased
in cSCC [59, 60, 79, 80]. Immunofluorescence detection of
pY705-STAT3 signal suggests an inverse correlation be-
tween the pY705-STAT3 subcelular localization and miR-
204 expression in AK and cSCC. Non-peritumoral distant
AKs showed phosphorylated STAT3 excluded from the
nuclei, whereas AKs adjacent to cSCC displayed nuclear
pY705-STAT3 signal when their corresponding tumors
were also positive for this marker. Nuclear p705-STAT3
signal in adjacent AKs and cSCC [59, 60] (our own data)
suggests that miR-204 already suffers a downregulation
in some areas of the AK that will progress to cSCC. On
the contrary, pY705-STAT3 signal at the plasma mem-
brane/cytoplasm in some of the non-peritumoral AKs
Fig. 6 Immunolocalization of pY705-STAT3 in AK and cSCC. a pY705-STAT3 signal detected by immunofluorescence in CSE skin, two representative
non-peritumoral AK lesions and in two AK lesions adjacent to cSCC. Scale bar, 50 μm. b Hematoxylin/eosin and pY705-STAT3 staining of cSCC. Observe
the intense pY705-STAT3 signal in tumor areas closer to the skin surface whereas the signal is lost in more infiltrative deep regions of the tumor. Scale
bar, 200 μm. c PTPN11 immunodetection in CSE skin, non-peritumoral AK and AK adjacent to cSCC. Scale bar, 50 μm
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suggests that certain degree of STAT3 activation is
already present in AK, but miR-204 expression would
inhibit the expression of proteins regulating effective
pY705-STAT3 translocation to the nucleus, where these
proteins act as transcription factors.
Conclusions
MicroRNA-204 may act as a “rheostat” that controls the
signaling towards the MAPK pathway or the STAT3 path-
way. MiR-204 would favour MAPK pathway and make the
AK cell insensitive to the induction of the STAT3 pathway
despite the presence of procarcinogenic inflammatory me-
diators. In most cSCCs, miR-204 promoter DNA methyla-
tion accounts for miR-204 silencing, which would result
in STAT3 activation and translocation to the nucleus, a
common feature found in 80 % of cSCCs.
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